MED MEDIFAST INC revenue, earnings and financials
For the quarter ended September 30, 2026, MEDIFAST INC reported revenue of $72.0M (down 19.4% from a year earlier), net income of −$17.5M and diluted EPS of −$1.57; over the last four quarters revenue was $300M and net income −$41.2M; for the fiscal year ended December 2025 revenue was $386M, down 36.0% on the year before.
MED annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $386M, gross profit $275M, operating income −$14.2M, net income −$19.0M (margin -4.9%), EPS −$1.70
- Fiscal year ended Dec 2024: revenue $602M, gross profit $445M, operating income $2.88M, net income $2.00M (margin 0.3%), EPS $0.19
- Fiscal year ended Dec 2023: revenue $1.07B, gross profit $776M, operating income $126M, net income $99.0M (margin 9.2%), EPS $9.10
- Fiscal year ended Dec 2022: revenue $1.60B, gross profit $1.14B, operating income $185M, net income $144M (margin 9.0%), EPS $12.73
- Fiscal year ended Dec 2021: revenue $1.53B, gross profit $1.13B, operating income $216M, net income $164M (margin 10.7%), EPS $13.89
MED quarterly revenue and earnings
- Quarter ended Sep 30, 2026: revenue $72.0M (down 19.4% year over year), net income −$17.5M, EPS −$1.57
- Quarter ended Jun 30, 2026: revenue $76.4M (down 27.6% year over year), net income −$3.10M, EPS −$0.28
- Quarter ended Mar 31, 2026: revenue $76.0M (down 34.3% year over year), net income −$2.12M, EPS −$0.19
- Quarter ended Dec 31, 2025 (from the annual report): revenue $75.1M (down 36.9% year over year), net income −$18.4M, EPS −$1.64
- Quarter ended Sep 30, 2025: revenue $89.4M (down 36.2% year over year), net income −$2.26M, EPS −$0.21
- Quarter ended Jun 30, 2025: revenue $106M (down 37.4% year over year), net income $2.48M, EPS $0.22
- Quarter ended Mar 31, 2025: revenue $116M (down 33.8% year over year), net income −$772K, EPS −$0.07
- Quarter ended Dec 31, 2024 (from the annual report): revenue $119M (down 37.7% year over year), net income $709K, EPS $0.08
- Quarter ended Sep 30, 2024: revenue $140M (down 40.6% year over year), net income $1.13M, EPS $0.10
- Quarter ended Jun 30, 2024: revenue $169M (down 43.1% year over year), net income −$8.15M, EPS −$0.75
- Quarter ended Mar 31, 2024: revenue $175M (down 49.9% year over year), net income $8.32M, EPS $0.76
- Quarter ended Dec 31, 2023 (from the annual report): revenue $191M (down 43.4% year over year), net income $5.62M, EPS $0.54
- Quarter ended Sep 30, 2023: revenue $236M (down 39.6% year over year), net income $23.1M, EPS $2.12
- Quarter ended Jun 30, 2023: revenue $296M (down 34.7% year over year), net income $30.3M, EPS $2.77
- Quarter ended Mar 31, 2023: revenue $349M (down 16.4% year over year), net income $40.0M, EPS $3.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $337M (down 10.7% year over year), net income $27.0M, EPS $2.45
- Quarter ended Sep 30, 2022: revenue $390M (down 5.6% year over year), net income $36.2M, EPS $3.27
- Quarter ended Jun 30, 2022: revenue $453M (up 15.0% year over year), net income $39.1M, EPS $3.42
- Quarter ended Mar 31, 2022: revenue $418M (up 22.6% year over year), net income $41.8M, EPS $3.59
- Quarter ended Dec 31, 2021 (from the annual report): revenue $378M, net income $34.0M, EPS $2.91
MED cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $6.86M, share buybacks $0, dividends $0.00 per share
- Fiscal year ended Dec 2024: operating cash flow $24.5M, share buybacks $0, dividends $0.00 per share
- Fiscal year ended Dec 2023: operating cash flow $148M, share buybacks $3.60M, dividends $4.95 per share
- Fiscal year ended Dec 2022: operating cash flow $195M, share buybacks $126M, dividends $6.56 per share
- Fiscal year ended Dec 2021: operating cash flow $94.5M, share buybacks $56.0M, dividends $5.68 per share
MED balance sheet
- Sep 30, 2026: cash $58.4M, total assets $240M, total liabilities $59.5M, shareholders' equity $180M
- Jun 30, 2026: cash $71.9M, total assets $260M, total liabilities $64.0M, shareholders' equity $196M
- Mar 31, 2026: cash $71.5M, total assets $252M, total liabilities $54.4M, shareholders' equity $198M
- Dec 31, 2025: cash $89.3M, total assets $248M, total liabilities $49.1M, shareholders' equity $199M
- Sep 30, 2025: cash $99.5M, total assets $268M, total liabilities $53.5M, shareholders' equity $215M
- Jun 30, 2025: cash $102M, total assets $269M, total liabilities $53.3M, shareholders' equity $216M
- Mar 31, 2025: cash $91.7M, total assets $280M, total liabilities $69.1M, shareholders' equity $211M
- Dec 31, 2024: cash $90.9M, total assets $284M, total liabilities $74.1M, shareholders' equity $210M
What is MED's revenue?
MEDIFAST INC reported $300M of revenue over its last four quarters, through September 30, 2026.
Is MED profitable?
No. MEDIFAST INC lost $41.2M over the last four quarters.
What is MED's EPS?
Diluted earnings per share over the last four quarters were −$3.68; −$1.57 in the latest quarter.
Does MED pay a dividend?
MEDIFAST INC paid $4.95 per share in dividends in the fiscal year ended December 2023.